Plain-English translation of NCT04837547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
The PEACH TRIAL is testing a personalized cancer treatment that combines two approaches: targeted drugs matched to your tumor's genetics, and adoptive cellular therapy—a technique that uses your own immune cells that have been trained to fight cancer. Researchers will enroll up to 24 children and young adults with either recurrent neuroblastoma or newly diagnosed diffuse intrinsic pontine glioma (DIPG), a type of brain stem tumor. The main goal is to determine the safest and most effective dose of this combined treatment.
Recurrent neuroblastoma and newly diagnosed DIPG are aggressive cancers with limited treatment options and poor survival rates. This trial exists because standard therapies often don't work well enough for these patients, and researchers believe combining personalized targeted therapy with immune-boosting cell therapy may offer a better chance at fighting these cancers.
You likely qualify if…
You likely don't qualify if…
You will first undergo a biopsy so doctors can study your tumor's genetic makeup and prepare personalized immune cells for you. Then you will receive the combination treatment, which includes injections or infusions of your trained immune cells along with targeted drugs, most likely in a hospital or clinic setting. The trial uses a careful dose-escalation approach, meaning early participants receive lower doses while doctors monitor safety before potentially increasing doses for later participants. The study team will closely watch for side effects and measure how well your cancer responds over time.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States